SyntheX is using the power of genetics and synthetic biology to build the next generation of drug discovery engines.
We discover and develop therapeutics for conventionally undruggable targets using functional selection to target currently inaccessible mechanisms of action.
Using genetically engineered circuits, our platform technologies rely on functional intracellular drug selection as opposed to in vitro screening. This allows us to discover compounds with novel modes of action that can modulate protein interactions in either orthosteric or allosteric ways.
We have developed ToRPPIDO to discover disruptors of protein-protein interactions, and ToRNeDO to discover molecular glue-based functional protein degraders using a pre-specified E3 ligase and a neosubstrate of interest.
Our platforms can use canonical small molecule HTS approaches or select from our proprietary genetically encoded peptide and rigidified scaffold libraries of billions of compounds.
Our internal programs are focused on oncology. We select targets based on oncogene addiction and synthetic lethality.
THE FOUNDING TEAM
Imagine. Design. Build. Create.
Are you an enthusiastic scientist who wants to bring therapies into the clinic? Do you want to use synthetic biology to advance drug discovery? We are always keeping an eye out for new talented members to join the team.